Baseline levels of low-density lipoprotein cholesterol and lipoprotein (a) and the AvaII polymorphism of the low-density lipoprotein receptor gene influence the response of low-density lipoprotein cholesterol to pravastatin treatment

• Published in: Metabolism, clinical and experimental Vol. 54; no. 6; pp. 741 - 747
• Main Authors: Lahoz, Carlos, Peña, Rocío, Mostaza, Jose M., Laguna, Fernando, García-Iglesias, María F., Taboada, Manuel, Pintó, Xavier
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2005
• Subjects: Adult; Aged; Cholesterol, LDL - blood; Deoxyribonucleases, Type II Site-Specific - metabolism; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use; Hypercholesterolemia - blood; Hypercholesterolemia - drug therapy; Hypercholesterolemia - genetics; Lipoprotein(a) - blood; Male; Middle Aged; Polymorphism, Genetic; Pravastatin - therapeutic use; Prospective Studies; Receptors, LDL - genetics

To investigate some individual and genetic factors that may influence the response of low-density lipoprotein cholesterol (LDL-C) to pravastatin treatment, we recruited 440 subjects with hypercholesterolemia (mean age, 57 years; 43% men) from 21 primary health care centers-outpatient clinics into a...